• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺髓样癌分级:一项观察者间可重复性研究。

Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.

机构信息

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.

Harvard Medical School, Boston, MA, USA.

出版信息

Endocr Pathol. 2022 Sep;33(3):371-377. doi: 10.1007/s12022-022-09718-0. Epub 2022 May 13.

DOI:10.1007/s12022-022-09718-0
Abstract

Grade, based on proliferative activity and tumor necrosis, has recently been shown to be prognostic in medullary thyroid carcinoma (MTC) in multivariate analysis. The aim of this study was to evaluate the interobserver reproducibility of assessed grade in MTC. Three groups (each group included one resident/fellow and one attending pathologist) independently evaluated a cohort of 44 sporadic MTC. For each case, all available tumor slides were reviewed, and mitotic count and the presence of tumor necrosis were recorded. Ki-67 was performed, and the Ki-67 proliferative index was determined in the area of highest proliferative activity. Tumors were graded according to the recently published International Medullary Thyroid Carcinoma Grading System (IMTCGS). Kappa statistics were calculated for each individual criterion (mitotic count, Ki-67 proliferative index, and necrosis) and for assigned IMTCGS grade. For our cohort of 44 MTCs, the kappa statistic for mitotic count, Ki-67 proliferative index, and necrosis was 0.68, 0.86, and 0.89, respectively. The kappa statistic for assigned IMTCGS grade was 0.87. Our findings indicate that there was a strong level of agreement for assessment of grade in our cohort of MTC, indicating that grade as assessed by the IMTCGS is not only prognostic but also reproducible.

摘要

在多变量分析中,最近发现分级(基于增殖活性和肿瘤坏死)在甲状腺髓样癌(MTC)中具有预后意义。本研究的目的是评估 MTC 中评估分级的观察者间可重复性。三个小组(每个小组包括一名住院医师/研究员和一名主治病理学家)独立评估了 44 例散发性 MTC 队列。对于每个病例,都回顾了所有可用的肿瘤切片,并记录了有丝分裂计数和肿瘤坏死的存在。进行了 Ki-67 检测,并在增殖活性最高的区域确定了 Ki-67 增殖指数。根据最近发表的国际甲状腺髓样癌分级系统(IMTCGS)对肿瘤进行分级。为每个单独的标准(有丝分裂计数、Ki-67 增殖指数和坏死)和分配的 IMTCGS 分级计算了 Kappa 统计量。对于我们的 44 例 MTC 队列,有丝分裂计数、Ki-67 增殖指数和坏死的 Kappa 统计量分别为 0.68、0.86 和 0.89。分配的 IMTCGS 分级的 Kappa 统计量为 0.87。我们的发现表明,在我们的 MTC 队列中,对分级的评估存在很强的一致性,这表明 IMTCGS 评估的分级不仅具有预后意义,而且具有可重复性。

相似文献

1
Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.甲状腺髓样癌分级:一项观察者间可重复性研究。
Endocr Pathol. 2022 Sep;33(3):371-377. doi: 10.1007/s12022-022-09718-0. Epub 2022 May 13.
2
Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.孤立性髓样甲状腺癌国际分级系统的独立验证:单中心经验。
Mod Pathol. 2023 Sep;36(9):100235. doi: 10.1016/j.modpat.2023.100235. Epub 2023 Jun 1.
3
Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation.用国际甲状腺髓样癌分级系统对细针抽吸细胞学标本进行甲状腺髓样癌分级:细胞学-组织学相关性。
Cancer Cytopathol. 2024 Apr;132(4):224-232. doi: 10.1002/cncy.22778. Epub 2023 Dec 8.
4
External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.单一机构队列中三种髓样甲状腺癌分级系统的外部验证。
Endocr Pathol. 2022 Sep;33(3):359-370. doi: 10.1007/s12022-022-09719-z. Epub 2022 May 18.
5
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.国际甲状腺髓样癌分级系统:甲状腺髓样癌的有效分级系统。
J Clin Oncol. 2022 Jan 1;40(1):96-104. doi: 10.1200/JCO.21.01329. Epub 2021 Nov 3.
6
Exploration of Digital Image Analysis for Ki67 Quantification in the Grading of Medullary Thyroid Carcinoma: A Pilot Study with 85 Cases.数字图像分析在甲状腺髓样癌分级中 Ki67 定量评估的探索:85 例初步研究
Head Neck Pathol. 2023 Sep;17(3):638-646. doi: 10.1007/s12105-023-01564-8. Epub 2023 Jun 9.
7
A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.基于增殖活性(Ki-67 和有丝分裂计数)和凝固性坏死的甲状腺髓样癌分级方案建议
Am J Surg Pathol. 2020 Oct;44(10):1419-1428. doi: 10.1097/PAS.0000000000001505.
8
International medullary thyroid carcinoma grading system: an Indian tertiary care centre experience.国际髓样甲状腺癌分级系统:一家印度三级医疗中心的经验
Eur Arch Otorhinolaryngol. 2024 Mar;281(3):1571-1579. doi: 10.1007/s00405-023-08341-x. Epub 2023 Nov 27.
9
Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.散发性甲状腺髓样癌的肿瘤分级及与生存相关的分子特征
Thyroid. 2024 Feb;34(2):177-185. doi: 10.1089/thy.2023.0482. Epub 2023 Dec 27.
10
Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas.散发性髓样甲状腺癌基因分型队列中分级的评估。
Histopathology. 2021 Sep;79(3):427-436. doi: 10.1111/his.14370. Epub 2021 Jun 15.

引用本文的文献

1
Validation of the International Medullary Thyroid Cancer Grading System and Identification of EZH2 as a Prognostic and Potential Therapeutic Marker in Medullary Thyroid Cancer.国际甲状腺髓样癌分级系统的验证及EZH2作为甲状腺髓样癌预后和潜在治疗标志物的鉴定
Cancers (Basel). 2025 Feb 21;17(5):737. doi: 10.3390/cancers17050737.
2
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.共识声明:甲状腺癌管理中可操作生物标志物检测的建议
Endocr Pathol. 2024 Dec;35(4):293-308. doi: 10.1007/s12022-024-09836-x. Epub 2024 Nov 23.
3
The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours.

本文引用的文献

1
Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center.Ki-67 标记指数在滤泡性甲状腺肿瘤中的预后价值:来自一家三级甲状腺中心的 20 年经验。
Endocr Pathol. 2022 Jun;33(2):231-242. doi: 10.1007/s12022-022-09714-4. Epub 2022 Mar 19.
前方的道路:2022年世界卫生组织内分泌和神经内分泌肿瘤分类导航简要指南
J Clin Pathol. 2024 Dec 18;78(1):1-10. doi: 10.1136/jcp-2023-209060.
4
Ki67 proliferation index in medullary thyroid carcinoma: a comparative study of multiple counting methods and validation of image analysis and deep learning platforms.甲状腺髓样癌中 Ki67 增殖指数:多种计数方法的比较研究及图像分析和深度学习平台的验证。
Histopathology. 2023 Dec;83(6):981-988. doi: 10.1111/his.15048. Epub 2023 Sep 14.
5
Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.孤立性髓样甲状腺癌国际分级系统的独立验证:单中心经验。
Mod Pathol. 2023 Sep;36(9):100235. doi: 10.1016/j.modpat.2023.100235. Epub 2023 Jun 1.
6
Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.甲状腺髓样微小癌的自然病史和预后预测因素。
J Clin Endocrinol Metab. 2023 Sep 18;108(10):2626-2634. doi: 10.1210/clinem/dgad173.
7
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.C 细胞神经内分泌肿瘤更新:甲状腺髓样癌的预后和预测的组织病理学和分子特征。
Endocr Pathol. 2023 Mar;34(1):1-22. doi: 10.1007/s12022-023-09753-5. Epub 2023 Mar 8.
8
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future.Ki67 增殖指数在神经内分泌和内分泌肿瘤中的诊断、预后和预测作用:过去、现在和未来。
Endocr Pathol. 2023 Mar;34(1):79-97. doi: 10.1007/s12022-023-09755-3. Epub 2023 Feb 17.